RSV-associated outcomes in the ISI-RSV risk groups stratified according to antiviral therapy at the URTI stage
| . | . | . | Antiviral therapy at the URTI stage . | . | |||
|---|---|---|---|---|---|---|---|
| No . | Yes . | ||||||
| Risk group . | No. . | LRTI, n (%) . | No. . | LRTI, n (%) . | No. . | LRTI, n (%) . | Risk ratio for lack of antiviral therapy (95% CI) . |
| Progression from URTI to LRTI | |||||||
| Low | 69 | 5 (7) | 25 | 4 (16) | 44 | 1 (2) | 7 (0.8-59.6) |
| Moderate | 147 | 22 (15) | 47 | 11 (23) | 100 | 11 (11) | 2.1 (0.9-4.6) |
| High | 21 | 10 (48) | 8 | 8 (100) | 13 | 2 (15) | 6.5 (1.8-23.6) |
| Death, n (%) | Death, n (%) | Death, n (%) | |||||
| Low | 69 | 0 | 25 | 0 | 44 | 0 | — |
| Moderate | 147 | 4 (3) | 47 | 2 (4) | 100 | 2 (2) | 2.1 (0.3-14.6) |
| High | 21 | 6 (29) | 8 | 5 (63) | 13 | 1 (8) | 8.1 (1.1-57.6) |
| . | . | . | Antiviral therapy at the URTI stage . | . | |||
|---|---|---|---|---|---|---|---|
| No . | Yes . | ||||||
| Risk group . | No. . | LRTI, n (%) . | No. . | LRTI, n (%) . | No. . | LRTI, n (%) . | Risk ratio for lack of antiviral therapy (95% CI) . |
| Progression from URTI to LRTI | |||||||
| Low | 69 | 5 (7) | 25 | 4 (16) | 44 | 1 (2) | 7 (0.8-59.6) |
| Moderate | 147 | 22 (15) | 47 | 11 (23) | 100 | 11 (11) | 2.1 (0.9-4.6) |
| High | 21 | 10 (48) | 8 | 8 (100) | 13 | 2 (15) | 6.5 (1.8-23.6) |
| Death, n (%) | Death, n (%) | Death, n (%) | |||||
| Low | 69 | 0 | 25 | 0 | 44 | 0 | — |
| Moderate | 147 | 4 (3) | 47 | 2 (4) | 100 | 2 (2) | 2.1 (0.3-14.6) |
| High | 21 | 6 (29) | 8 | 5 (63) | 13 | 1 (8) | 8.1 (1.1-57.6) |
We observed a significant trend of increasing incidence of progression from URTI to LRTI and RSV-associated mortality with increased risk (P < .001). These trends were maintained even when we stratified the patients according to antiviral therapy. The incidence of both outcomes decreased when antiviral therapy was administered at the URTI stage.